- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00791141
Adjuvant Cetuximab and Chemoradiation in Head and Neck Cancer (ACCRA-HN)
Multicenter, Open-label Phase II Trial on Post-surgery Chemoradiation in Combination With Cetuximab in Squamous Cell Carcinoma of the Head and Neck With High Risk of Locoregional Recurrence.
Study Overview
Detailed Description
Advanced squamous cell carcinoma of the head and neck still has a poor prognosis and loco-regional recurrence frequently occurs. Efforts have been made to improve response rates and survival and different therapeutic regimens including concurrent chemo-radiotherapy or sequential chemo-radiotherapy have been developed.
To further increase the outcome of patients with locally advanced SCCHN effective new treatments with minimal toxicities are needed. Molecular targeted agents, which do not demonstrate overlapping toxicities with commonly used chemotherapy agents, have therefore been investigated. The EGFR is widely expressed at high levels in SSCHN and is associated with poor prognosis.
Cetuximab has already been investigated in combination with radiotherapy or chemotherapy in patients with head and neck cancer. The immunoradiotherapy was well tolerated with most of the side effects related to the high dose irradiation. The most common side effects are mucositis and dysphagia. Additionally, skin reactions appear sometimes more frequently in cetuximab administration. Grade 3 to 4 infusion reactions were observed in 3% of the patients treated with cetuximab. Based on the current promising results with RCT in patients with locally advanced head and neck cancer and clinical results with EGFR-antibodies plus RT, the present study was primarily designed to define the acute grade 3/4 toxicity.
We expect to show effective results in reducing the risk of distant metastasis, with administration of an additional six month adjuvant cetuximab treatment, in patient with recurrent SCCHN.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 13353
- Charité University Medicine, Department of Radiotherapy and Radiological Oncology
-
-
BW
-
Freiburg, BW, Germany, 79106
- Department of Radiotherapeutics of the University Hospital Freiburg
-
Heidelberg, BW, Germany, 69120
- Department of Radiological Oncology University Hospital Heidelberg
-
Tuebingen, BW, Germany, 72076
- Department of Radiotherapy and Radiological Oncology University Hospital Tuebingen
-
Ulm, BW, Germany, 89091
- Department of Radiotherapy and Radiological Oncology University Hospital Ulm
-
-
Bavaria
-
Munich, Bavaria, Germany, 81377
- Department of Radiotherapy and Radiological Oncology, University Hospital Munich
-
-
NW
-
Essen, NW, Germany, 45122
- Department of Radiotherapy an Radiological Oncology University Hospital Essen
-
-
Rheinland-Pfalz
-
Mainz, Rheinland-Pfalz, Germany, 55131
- Department of Radiotherapy and Radiological Oncology University Hospital Mainz
-
-
Schleswig Hostein
-
Lübeck, Schleswig Hostein, Germany, 23538
- Department of Radiotherapy, University Hospital Schleswig Holstein, Campus Lübeck
-
-
Thueringen
-
Jena, Thueringen, Germany, 07743
- Department of Radiotherapy and Radiological Oncology Universität Hospital Jena
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed written informed consent;
- Males or females between 18 and 70 years of age;
- Surgically resected squamous cell carcinomas of the hypopharynx, oropharynx, larynx and oral cavity with high risk of locoregional recurrence not more than 6-9 weeks (maximum) ago;
To be categorized as high risk patients have to fulfil at least one of the following criteria:
- R0 - resection <5 mm margin
- R1 - resection
- Extracapsular nodal extension;
- no previous chemotherapy, radiotherapy;
- Performance status ECOG: 0 - 1;
- Contraception in male and female patients if of childbearing potential, willingness to use effective contraceptive method for the study duration and 2 months post-dosing;
Adequate renal, liver and hematological functions (within maximum 9 weeks until surgery):
- Adequate bone marrow function: neutrophils > 1.5 x 10^9/L, platelets > 100 x 10^9/L, hemoglobin > 10.0 g/dL
- Adequate liver function: Bilirubin < 2.0 mg/dL, AST, ALT, AP, γ-GT < 3 x ULN
- Adequate renal function: creatinine clearance > =60 ml/min
- No distant metastases;
Exclusion Criteria:
- Nasopharyngeal carcinoma;
- R2 resection;
- Invalid informed consent;
- Performance Status > 1;
- Previous chemotherapy or radiotherapy for carcinoma of the head and neck;
- Prior exposure to EGFR pathway targeting therapy;
Other serious illness or medical conditions:
- Unstable cardiac disease despite treatment, congestive heart failure NYHA grade 3 and 4;
- Clinically significantly abnormal electrocardiogram (ECG) or left ventricular ejection fraction (LVEF) below the institutional range of the normal
- Significant neurologic or psychiatric disorders including dementia or seizures;
- Active uncontrolled infection;
- Active disseminated intravascular coagulation;
- Other serious underlying medical conditions which could impair the ability of the patient to participate in the study;
- Symptomatic peripheral neuropathy National Cancer Institute-Common Toxicity Criteria (NCI-CTC v3.0) grade 2 or ototoxicity grade 2, except if due to trauma or mechanical impairment due to tumor mass;
- Having participated in another therapeutic clinical trial or any investigational agent in the preceding 30 days;
- Known allergic/hypersensitivity reaction to any of the components of the treatment;
- Pregnancy (absence confirmed by serum/urine β-HCG) or breast-feeding;
- Known drug abuse;
- Other previous malignancy within 5 years, with exception of a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix;
- Legal incapacity or limited legal capacity;
- Sensitivity and incompatibility against 5-Fluorouracil
- Sensitivity and incompatibility against platinum-compounds
- Known incompatibilities >grade 3 towards cetuximab
- expected incompliance of patient (e.g. in case of severe alcohol addiction)
- Dental evaluation: Pre treatment dental care before start of radiochemotherapy (approximately 8 to 10 days lapse-time is needed for complete recovery before initiation of radiation therapy).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Cetuximab
Cetuximab in combination with radiotherapy, cisplatin and 5-FU.
After chemoradiotherapy all patients receive a cetuximab maintenance therapy.
|
Loading dose prior to chemoradiotherapy 400 mg/m², followed by every week infusion of 250 mg/m² during chemoradiotherapy.
After chemoradiotherapy every 2 week infusions of 500 mg/m² over 6 months.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of patients experiencing grade 3/4 acute toxicities not considering grade 3/4 skin tox. outside the radiation portals combined with 2-years disease-free survival rate.
Time Frame: any toxicities occurring within 90 days post radiation start
|
any toxicities occurring within 90 days post radiation start
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of Loco-regional relapse
Time Frame: assessment after patient has completed follow-up
|
assessment after patient has completed follow-up
|
Disease-free survival
Time Frame: time from start of surgery to the first evidence of loco-regional or distant tumor relapse or death
|
time from start of surgery to the first evidence of loco-regional or distant tumor relapse or death
|
Progression-free survival
Time Frame: from start of surgery to the first observation of disease progression or death
|
from start of surgery to the first observation of disease progression or death
|
Overall survival
Time Frame: censored at the time of last documented efficacy
|
censored at the time of last documented efficacy
|
The rate of patients with secondary primary neoplasm
Time Frame: assessment after patient has completed follow-up
|
assessment after patient has completed follow-up
|
The incidence of late toxicity
Time Frame: beyond 90 days after start of radiation therapy
|
beyond 90 days after start of radiation therapy
|
Collaborators and Investigators
Investigators
- Principal Investigator: Wilfried Budach, Prof. Dr., Department of Radiotherapy and Radiological Oncology
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ACCRA-HN
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Cancer
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
Mayo ClinicRecruitingCancer Head Neck | Cancer Neck | Cancer, HeadUnited States
-
IRCCS Policlinico S. MatteoNestlé Health Science Spain; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
Chinook Therapeutics, Inc. (formerly Aduro)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedHead And Neck CancerUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
Radboud University Medical CenterUnknown
-
Centre Oscar LambretUnknownEpidermoid Head and Neck CancerFrance
Clinical Trials on Cetuximab
-
University Medical Center GroningenUMC Utrecht; Erasmus Medical CenterRecruitingHead and Neck Squamous Cell Carcinoma | Margin AssessmentNetherlands
-
West China HospitalFirst Affiliated Hospital of Chongqing Medical UniversityRecruitingColo-rectal Cancer | Capecitabine | CetuximabChina
-
Amsterdam UMC, location VUmcRadboud University Medical Center; University Medical Center GroningenTerminatedMetastatic Colorectal CancerNetherlands
-
Eben RosenthalNational Cancer Institute (NCI)TerminatedPancreatic AdenocarcinomaUnited States
-
HiberCell, Inc.TerminatedColorectal CancerUnited States, Puerto Rico, Germany, France
-
Merck KGaA, Darmstadt, GermanyCompletedPreviously Untreated Metastatic Colorectal CancerFrance, Italy, Poland, Germany, Hong Kong, Austria, Brazil, Israel, Greece, Argentina, Thailand, Belgium, Australia, Mexico
-
Arbeitsgemeinschaft medikamentoese TumortherapieMerck Sharp & Dohme LLCCompleted
-
Cancer Institute and Hospital, Chinese Academy...Recruiting
-
Poitiers University HospitalCompletedMetastatic Colon CancerFrance
-
Cliniques universitaires Saint-Luc- Université...Merck Sharp & Dohme LLC; Merck Serono International SACompleted